800-872-2273

Clinical Trials and Studies

Your participation matters. Help us discover and cure!

Contact us at (800) USC-CARE (800-872-2273)

We're sorry, but this trial is no longer enrolling volunteers.

A Prospective, Multi-Center, Randomized, Double-Masked, Positive-Controlled Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis

Description

Detailed Description
Anterior uveitis is a disorder of the eye associated with intraocular inflammation of the anterior portion of the uvea, particularly the iris and/or ciliary body. It is distinct from other iterations of uveitis such as posterior, diffuse and intermediate uveitis although it is the most common form of uveitis and accounts for approximately 75% of cases. In a Phase 1/2 study (EGP-437-001), the delivery of EGP-437 (40 mg/mL dexamethasone phosphate solution) at four different iontophoresis dose levels was studied in 40 subjects with non-infectious anterior segment uveitis. The study demonstrated that a single EGP-437 treatment: lowered anterior chamber cell (ACC) scores in the majority of patients without requiring additional treatment; produced low short-term systemic exposure to dexamethasone and dexamethasone phosphate; and produced the most beneficial effects in the 1.6 and 4.8 mA-min dose groups; and caused mainly minor AEs and no non-ocular systemic corticosteroid mediated effects were observed. The Phase 3 study is intended to confirm and extend the results from the Phase 2 study. The study is designed to assess the safety and efficacy Ocular Iontophoresis with EGP-437 4.0 mA-min at 1.5 mA and accompanying placebo eyedrops in comparison to Ocular Iontophoresis with sodium citrate buffer solution 4.0 mA-min at 1.5 mA and accompanying prednisolone acetate (1%) eyedrops for the treatment of non-infectious anterior segment uveitis.

Phase

Phase 3 - a treatment has shown activity against a particular disease, where it is either added to existing treatment or compared to the standard treatment.

Inclusion and Exclusion Criteria

  • Male or female, age 12 to 85 years with a diagnosis of non-infectious anterior segment uveitis defined as an anterior chamber cell count of ≥ 11 cells
  • Receive, understand, and sign a copy of the written informed consent form
  • Be able to return for all study visits and willing to comply with all study-related instructions

  • Have uveitis of infectious etiology
  • Have active intermediate or posterior uveitis
  • Known positive HLA-B27 with a severe (4+) fibrinoid reaction
  • Have previous anterior segment uveitis episode in the study eye ≤ 4 weeks prior to baseline visit
  • Have used topical corticosteroid treatment in the study eye ≤ 48 hours prior to baseline visit
  • Have used oral corticosteroid within the past 14 days prior to baseline
  • Have received intravitreal or sub-Tenon corticosteroid treatment in the study eye within the past 6 months prior to baseline visit
  • Currently using prescribed nonsteroidal anti-inflammatory agents (i.e., use of over-the-counter dosages is allowable) or prescribed immunosuppressive agents, unless the dose has been stable for the last six weeks and no change in dosing is anticipated for the duration of the study
  • Have IOP ≥ 25 mmHg at baseline, a history of glaucoma, or require ocular anti-hypertensive medications in the study eye
  • Be known steroid intraocular pressure responders in either eye
  • Have open wounds/skin disease on the forehead area where the iontophoresis return electrode will be applied
  • Have severe lesions of the eyelids or the ocular surface impeding the application of the iontophoresis applicator
  • Have known allergy to dexamethasone or dexamethasone phosphate or any medication to be used in this study
  • Have history or diagnosis of ocular herpes, corneal lesion of suspected herpetic origin, or Beh

Sites

  • California

    • Doheny Eye Medical Group, Los Angeles, California, 90033
    • Retina-Vitreous Associates Medical Group, Beverly Hills, California, 90211
    • Orange County Retina Medical Group, Santa Ana, California, 92705

  • Arizona

    • Associated Retina Consultants, Phoenix, Arizona, 85020
    • Arizona Eye Center, Chandler, Arizona, 85225

  • Colorado

    • Colorado Retina Associates, Golden, Colorado, 80401
    • Corneal Consultants of Colorado, Littleton, Colorado, 80120

  • Oregon

    • Casey Eye Institute, Portland, Oregon, 97239

  • Washington

    • Spokane Eye Clinical Research, Spokane, Washington, 99204

  • Texas

    • Medical Center Ophthalmology Associates, San Antonio, Texas, 78240
    • Austin Retina Associates, Austin, Texas, 78705
    • Houston Eye Associates, Houston, Texas, 77025

  • Missouri

    • Tauber Eye Center, Kansas City, Missouri, 64111
    • Comprehensive Eye Care Ltd., Washington, Missouri, 63090
    • Lifelong Vision Foundation, Chesterfield, Missouri, 63017

  • Tennessee

    • Southern College of Optometry, Memphis, Tennessee, 38104

  • Illinois

    • Illinois Retina Associates, Chicago, Illinois, 60612

  • Alabama

    • Department of Ophthalmology at University of Alabama at Birmingham, Birmingham, Alabama, 35233

  • Indiana

    • Raj K. Maturi, M.D. PC, Indianapolis, Indiana, 46290

  • Georgia

    • Advanced Eye Care, Fort Oglethorpe, Georgia, 30742
    • Emory Eye Center, Atlanta, Georgia, 30322
Powered by SC CTSI